A sugar-processing defect in the brain, and a supplement that made it worse in mice

A study published 9 June in Nature Metabolism identifies a specific metabolic process — excess production of glycans, the sugar chains attached to proteins and lipids throughout the body — as a driver of Alzheimer's disease pathology, and finds that a common over-the-counter supplement implicated in that same process, glucosamine, worsened cognitive outcomes in a mouse model of the disease [s1].

The research, led by scientists at the University of Florida's College of Medicine, combines several lines of evidence that individually would be suggestive and together make a stronger case: spatial metabolomics, lipidomics and glycomics in transgenic Alzheimer's mouse models; postmortem tissue from human Alzheimer's patients; and a retrospective analysis of electronic health records [s1].

What "hyperglycosylation" means and why it matters

Glycosylation is a normal, essential process — cells routinely attach sugar chains to proteins and lipids as part of how those molecules fold, function, and signal to each other. The paper's authors report a consistent, elevated pattern of this process in the brains of Alzheimer's mouse models and in postmortem tissue from human Alzheimer's patients, which they term hyperglycosylation [s1]. Using spatial isotopic tracing — a technique that follows labeled atoms through tissue over time — the team determined that this hyperglycosylation is driven by increased glycan biosynthesis, meaning the brain is producing more of these sugar chains rather than simply failing to clear them [s1].

The causal test: turning the pathway down, and turning it up

The strongest evidence in the paper for hyperglycosylation actually driving disease, rather than merely accompanying it, comes from two experiments that pushed the pathway in opposite directions. When researchers used genetic knockdown to reduce the enzymes responsible for glycan biosynthesis, cognitive outcomes improved in the Alzheimer's mouse models [s1]. When they instead gave the mice oral glucosamine supplementation — which feeds into the same glycan-production pathway — cognitive outcomes worsened [s1].

That paired result is what elevates this from correlation to a mechanistic claim: reducing the pathway helped, and feeding the pathway hurt, in the same experimental system.

The human records analysis, and its real limits

The paper's authors also report a retrospective analysis of electronic health records from patients with Alzheimer's disease, at varying stages of severity, and find that glucosamine supplementation was associated with accelerated disease progression and worse survival [s1].

This part of the study needs to be read with real caution, for reasons the mouse experiments do not share. A retrospective records analysis cannot establish that glucosamine caused faster decline in people the way the controlled mouse experiments can for mice — patients who take glucosamine, a supplement commonly used for joint pain, may differ from those who do not in ways related to age, mobility, comorbidity burden, or disease stage that the analysis may not fully account for. The published abstract does not report the specific sample size, effect size, or statistical adjustment used in this portion of the study, so this article does not attach numbers to the human finding beyond what the authors themselves describe: an association with accelerated progression and worsened survival [s1].

What this does and does not show

This is not evidence that glucosamine causes Alzheimer's disease, and the authors' own framing does not make that claim. It is evidence, from a controlled animal model, that a supplement which feeds a newly identified disease-associated metabolic pathway worsened outcomes in mice that already had Alzheimer's-like pathology — paired with an observational signal in human patients pointing the same direction. The mouse finding is specific to animals already modeling the disease; it says nothing about effects of glucosamine in people without Alzheimer's or without the underlying glycan dysregulation the paper describes.

The paper's broader contribution is identifying glycan metabolism as what its authors call "an actionable target" in Alzheimer's disease [s1] — meaning a pathway that could, in principle, be targeted pharmacologically, distinct from the amyloid and tau pathways that have dominated Alzheimer's drug development. That is a mechanistic proposal for future research, not a treatment available now.

What to watch

Whether independent labs replicate the hyperglycosylation finding in other Alzheimer's models. Whether follow-up research quantifies the human glucosamine association with sample sizes and effect estimates that allow the risk to be sized rather than only signed. And whether glycan biosynthesis enzymes become a target of active drug development, given the genetic knockdown result the paper reports.

This article describes findings from animal models and a retrospective records analysis. It is not medical advice, and readers with questions about supplement use, including glucosamine, should discuss them with a clinician rather than treating this study as guidance on what to take or avoid.

Sources

• [s1] Hawkinson, T.R., et al., "Hyperglycosylation is a metabolic driver of Alzheimer's disease," Nature Metabolism, published online 9 June 2026. https://doi.org/10.1038/s42255-026-01538-4